Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVersarien Regulatory News (VRS)

Share Price Information for Versarien (VRS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.1075
Bid: 0.105
Ask: 0.11
Change: 0.00125 (1.18%)
Spread: 0.005 (4.762%)
Open: 0.10625
High: 0.00
Low: 0.00
Prev. Close: 0.10625
VRS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Changes

18 Jul 2023 16:31

RNS Number : 4187G
Versarien PLC
18 July 2023
 

18 July 2023

 

Versarien plc

 

("Versarien" or the "Company")

 

Directorate Changes

 

Versarien plc (AIM: VRS), the advanced materials engineering group, is pleased to announce the appointment of Dr Stephen Hodge, currently the Company's Chief Technology Officer, as the Company's Chief Executive Officer with immediate effect.

 

Dr Stephen Hodge joined Versarien in 2017 and was appointed Head of Research in July 2018, before being appointed to the Board as Chief Technology Officer in January 2021. Prior to this, he was employed as a Principal Engineer at Cambridge Graphene Limited, a supplier of graphene inks and other graphene materials, and a subsidiary of Versarien. He has also held post-doctoral research associate positions at the Cambridge Graphene Centre, a research centre attached to the Department of Engineering at the University of Cambridge, and in the Department of Chemistry at Imperial College London, where he also completed a PhD in Nanomaterial Chemistry.

 

Stephen is a member of a number of advisory boards including holding the role of Chairman of the Technical Working Group within the Graphene REACH registration consortium. Last year Dr Hodge was awarded the Royal Society of Chemistry Rising Star in Industry Award 'for strategic leadership in developing greener solutions and advocating for global regulations related to the physical and toxicological testing of graphene'.

 

Resignation of Director

 

The Company has today received confirmation that Neill Ricketts has resigned from the Board with effect from 14 July 2023 and is no longer a Director of the Company. He continues on garden leave with no day-to-day responsibilities unless required by the Company.

 

Diane Savory, Non-executive Chair of Versarien, commented:

 

"I am very pleased that we are announcing the appointment of Stephen Hodge as Versarien's Chief Executive Officer. Stephen has been with Versarien for the past six years during which time he has been instrumental in the development of the Company's advanced materials technology and progressing our commercial relationships. I believe he is ideally placed to lead the Company as we continue to progress our turnaround strategy and focus on the development and commercialisation of Cementene™ and Graphene-Wear™.

 

"On behalf of the Board I would like to thank Neill Ricketts for his contribution to the Company since its formation and we wish him well in his future endeavours.

 

"We look forward to updating shareholders on the continuing progress with our turnaround strategy in the coming months."

 

For further information please contact:

 

Versarien

Stephen Hodge, Chief Executive Officer

Chris Leigh, Chief Financial Officer

c/o IFC

SP Angel Corporate Finance (Nominated Adviser and Broker)

Matthew Johnson, Adam Cowl

+44 (0)20 3470 0470

 

 

IFC Advisory Limited (Financial PR and Investor Relations)

Tim Metcalfe, Zach Cohen

+44 (0) 20 3934 6630

 

About Versarien:

 

The strategy of Versarien plc (AIM:VRS) is to be a development led advanced materials company focussed on specific sectors that will lead to a light manufacturing and licensing model.

 

For further information please see: http://www.versarien.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOANKFBBPBKDFOD
Date   Source Headline
28th Mar 20247:00 amRNSAudited Results for year ended 30 September 2023
28th Mar 20247:00 amRNSTotal Voting Rights
20th Mar 20248:33 amRNSPlacing to raise £615,000
14th Mar 20247:00 amRNSSouth American Graphinks Agreements
11th Mar 20247:00 amRNSSale of Korean Assets and Licencing of IP
16th Feb 20242:22 pmRNSNotification of final results
7th Feb 20247:00 amRNSReceipt of Legal Claims
31st Jan 20247:00 amRNSTotal Voting Rights
23rd Jan 20244:53 pmRNSHolding(s) in Company
23rd Jan 20241:24 pmRNSHolding(s) in Company
19th Jan 20247:00 amRNSPlacing to raise £400,000
10th Jan 202411:29 amRNSResult of General Meeting
20th Dec 20237:00 amRNSCompany Update and Notice of General Meeting
30th Nov 20237:00 amRNSTotal Voting Rights
8th Nov 20237:00 amRNSPlacing to raise £454,822
30th Oct 202311:52 amRNSResult of General Meeting
30th Oct 20237:00 amRNSGeneral Meeting Statement
12th Oct 20237:00 amRNSNotice of General Meeting
2nd Oct 20237:00 amRNSCorporate Update
13th Sep 20237:00 amRNSTurnaround Strategy - Gnanomat Grant Award
31st Jul 20237:00 amRNSTotal Voting Rights
18th Jul 20234:31 pmRNSDirectorate Changes
14th Jul 20237:00 amRNSPlacing to raise £650,000
4th Jul 202310:54 amRNSResult of General Meeting
4th Jul 20237:00 amRNSGeneral Meeting Statement
15th Jun 20237:00 amRNSNotice of General Meeting
9th Jun 20237:00 amRNSInterim Results
31st May 20237:00 amRNSTotal Voting Rights
17th May 20237:00 amRNSSuccessful Cementene precast concrete trials
3rd May 20239:30 amRNSPlacing and Update on Turnaround Strategy
31st Mar 20237:00 amRNSTotal Voting Rights
29th Mar 202311:22 amRNSResult of AGM
29th Mar 20237:00 amRNSAGM Statement
15th Mar 20237:00 amRNSPlacing to raise £318,000
14th Mar 20232:56 pmRNSFurther re Resignation of Chief Executive Officer
10th Mar 20237:00 amRNSResignation of Chief Executive Officer
6th Mar 20237:00 amRNSCostain Civil Engineering Project
1st Mar 202312:00 pmRNSUmbro Launch
28th Feb 20237:00 amRNSNotice of AGM and Posting of Annual Report
21st Feb 20237:00 amRNSResults for the 18 months ended 30 September 2022
9th Feb 20238:33 amRNSAIM Rule 17 Update
27th Jan 20237:00 amRNSGraphene-Wear OEKO-TEX Eco Passport certification
24th Jan 20231:56 pmRNSFinal Results Update
30th Dec 20227:00 amRNSTotal Voting Rights
6th Dec 20229:40 amRNSPlacing to raise £1.85 million
5th Dec 20224:40 pmRNSSecond Price Monitoring Extn
5th Dec 20224:35 pmRNSPrice Monitoring Extension
5th Dec 20227:00 amRNSG-SCALE Update & Innovate UK Loan Variation
2nd Dec 20224:35 pmRNSPrice Monitoring Extension
1st Dec 20224:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.